SEC Filing Summary: Rexahn Pharmaceuticals, Inc. (Form 8-K)
Business Context and Reporting Period
This Form 8-K was filed by Rexahn Pharmaceuticals, Inc. on October 9, 2007, reporting events occurring as of October 3, 2007. The filing discloses the entry into a material definitive agreement regarding the employment of the Company's Chief Financial Officer. Note: The request metadata references "Opus Genetics, Inc.," but the filing text explicitly identifies the registrant as Rexahn Pharmaceuticals, Inc.
Key Financial Metrics
This filing does not contain financial statements, revenue, profit, cash flow, margin, debt, or liquidity data. The only financial figures disclosed relate to executive compensation:
- Base Salary: $160,000 annually for the CFO.
- Annual Cash Bonus: Up to 50% of the annual base salary, at the CEO's discretion.
- Equity: Eligibility for stock options and additional cash/stock bonuses at the Board's discretion.
Material Changes
The primary material change is the formalization of the employment terms for Tae Heum Jeong, the Chief Financial Officer, effective September 12, 2007. The agreement establishes a fixed term through September 12, 2009, after which employment becomes "at-will" unless extended in writing.
Outlook, Risks, and Contingencies
The filing details specific termination contingencies and severance obligations:
- Termination without Cause: Entitles the CFO to accrued salary, pro-rata bonus (up to 50%), 6 months of base salary, and 18 months of health insurance coverage, subject to mitigation and release requirements.
- Change of Control: If terminated without Cause within one year of a Change of Control, severance increases to one year of base salary.
- Restrictions: The CFO is restricted from soliciting employees or customers for 12 months post-employment.
- Section 409A: Payments may be delayed by six months if the CFO is deemed a "specified employee" under Section 409A of the Internal Revenue Code.
Investor Verification Checklist
- Verify the correct registrant name (Rexahn Pharmaceuticals, Inc.) versus the metadata provided (Opus Genetics, Inc.).
- Review the full text of the Employment Agreement (Exhibit 10) for specific definitions of "Cause," "Disability," and "Change of Control."
- Assess the impact of the 6-month and 1-year severance obligations on the Company's cash reserves, given the lack of disclosed liquidity data in this filing.
- Confirm the status of the Company's Stock Option Plan to evaluate the potential dilution from future option awards to the CFO.